Objective: To compare cognitive behaviour therapy (CBT) with CBT plus medication; medication alone; and placebo in the treatment of adult obsessive-compulsive disorder (OCD).
Method: Forty-eight participants (43 completers) were recruited into two protocols. In the first protocol, 21 people with OCD were randomly allocated to either a standard medication (fluvoxamine) or standard placebo condition for a 5-month period. Both these groups subsequently received CBT for a further 5 months. In the second protocol, 22 people with OCD received CBT, one group was already stabilized on an antidepressant of choice; the second group was drug naïve.
Results: All active treatments, but not the placebo, showed clinical improvement. There was no difference in treatment response to CBT regardless of whether participants had previously received medication or placebo.
Conclusion: CBT has a more specific antiobsessional effect than medication but CBT plus medication shows greatest overall clinical improvement in mood.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0447.2006.00767.x | DOI Listing |
Appl Neuropsychol Child
January 2025
Department of Psychology and Neuroscience Center, Brigham Young University, Provo, USA.
Chronic stage neuropsychological assessments of children with severe TBI typically center around a referral question and focus on assessing cognitive, behavioral, and emotional functioning, making differential diagnoses, and planning treatment. When severe TBI-related neurological deficits are subtle and fall outside commonly assessed behavioral indicators, as can happen with theory of mind and social information processing, they can go unobserved and subsequently fail to be assessed. Additionally, should chronic stage cognitive, behavioral, and emotional assessment findings fall within the average to above average range, a child experiencing ongoing significant unassessed severe TBI-related subtle deficits could be mistakenly judged to have "recovered" from their injury; and to be experiencing no significant ongoing residual neurological deficits.
View Article and Find Full Text PDFPaediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFGeroscience
January 2025
Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
A healthy diet is a key determinant of successful aging. However, the psychological, social, and physiological changes associated with ageing often disrupt dietary behaviours. Hungary has one of the highest rates of chronic age-related diseases in the European Union, exacerbated by unhealthy dietary patterns and rapid population aging.
View Article and Find Full Text PDFJ Neurooncol
January 2025
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
Background: Medulloblastoma is the most commonly occurring malignant brain tumor of childhood. Treatment includes a combination of surgery, radiation therapy, and chemotherapy, all of which are associated with cognitive impairments. Despite appreciation of the value of neuropsychological evaluations to assess for cognitive impairments, there are barriers to these evaluations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!